共 50 条
- [21] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumoursBJC Reports, 3 (1):J. Randolph HechtJean-Marie MichotDavid BajorAmita PatnaikKi Y. ChungJudy WangGerald FalchookJames M. ClearyRichard KimAnuradha KrishnamurthyOmkar MaratheHagop YoussoufianCatherine EllisAngela WaszakSrimoyee GhoshHailei ZhangKaitlin YablonskiShruti D. ShahIvan Diaz-PadillaSusanna Ulahannan
- [22] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trialCancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103Amita PatnaikGlen J. WeissDrew W. RascoLisa BlaydornAmy MirabellaMurali BeeramWei GuoSharon LuHadi DanaeeKristen McEachernEllie ImJasgit C. Sachdev
- [23] Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyBritish Journal of Cancer, 2018, 119 : 538 - 545Hongnan MoJing HuangJiachen XuXuelian ChenDawei WuDong QuXi WangBo LanXingyuan WangJianping XuHonggang ZhangYihebali ChiQing YangBinghe Xu
- [24] Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyBRITISH JOURNAL OF CANCER, 2018, 119 (05) : 538 - 545Mo, HongnanHuang, JingXu, JiachenChen, XuelianWu, DaweiQu, DongWang, XiLan, BoWang, XingyuanXu, JianpingZhang, HonggangChi, YihebaliYang, QingXu, Binghe
- [25] A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCCONCOLOGIST, 2024, 29 : S7 - S7Kim, Miso
- [26] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCCJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Cho, Byoung ChulHamid, OmidZhu, XinhuaKeam, BhumsukKaczmar, John M.Williamson, Stephen K.Birnbaum, Ariel E.Dowlati, AfshinDy, Grace K.Hager, Steven JeffreyLynce, FilipaMcDermott, Raymond S.Sarker, DebashisWeise, Amy M.Yap, Timothy A.Yilmaz, EmrullahFang, FangMani, JayakumarKroog, Glenn ScottPapadopoulos, Kyriakos P.
- [27] Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Ma, Vincent T.Milhem, Mohammed M.Hidalgo, ManuelShields, Anthony F.Segar, Jennifer MargaretKhalil, MayaDavis, Andrew A.Verschraegen, Claire F.Wong, Deborah J. L.Schilder, Russell J.Gao, XinPowderly, John D., IIJiang, YixingAggarwal, Rahul RajAwan, Farrukh TauseefMcKean, MeredithChow, Warren AllenYao, ShengKeegan, PatriciaNaing, Aung
- [28] A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumoursANNALS OF ONCOLOGY, 2019, 30 : 191 - +Krauss, J.Eigentler, T.Schreiber, J.Weishaupt, C.Terheyden, P.Heinzerling, L.Mohr, P.Weide, B.Ochsenreither, S.Gutzmer, R.Becker, J. C.Kiecker, F.Funkner, F.Heidenreich, R.Kays, S-K.Klinkhardt, U.Gnad-Vogt, U. S.Scheel, B.Schoenborn-Kellenberger, O.Seibel, T.
- [29] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or LymphomaTARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733Gong, JifangGuo, YeZhang, YanqiaoBa, YiChen, TongLi, WeiZhou, CaicunWang, MengzhaoYang, HaiyanZhou, YuhongCai, QiqingWang, ZipingHuang, GangZhang, WeiSu, RilaCai, ZhonghengYue, ZenglianDou, JinzhouLi, PeiqiWu, RachelTse, Archie N.Shen, Lin
- [30] A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2025,Liu, DanGong, JifangZhang, JianShu, YongqianWu, HaoLiu, TianshuXu, YanhuaZhang, LijiaLi, MinHu, XichunShen, Lin